U.S. Packaging Stock News

NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Assessing Ligand Pharmaceuticals (LGND) Valuation After Recent Share Price Weakness And Strong 1 Year Return

Event context and recent stock performance Ligand Pharmaceuticals (LGND) has come into focus after a period in which its shares have moved lower over the past month and past 3 months, while still showing a positive 1 year total return. At a last close of US$183.83, the company carries a value score of 3, with annual revenue of US$251.233 million and net income of US$48.581 million, supported by positive annual revenue and net income growth. See our latest analysis for Ligand...
NYSE:ATMU
NYSE:ATMUMachinery

Atmus Filtration Technologies (ATMU) Margin Expansion Reinforces Bullish Earnings Narratives

Atmus Filtration Technologies (ATMU) has capped FY 2025 with Q4 revenue of US$446.6 million and basic EPS of US$0.59. Trailing twelve month revenue landed at US$1.76 billion with EPS of US$2.52 and net income of US$207.4 million. The company has seen quarterly revenue move from US$403.7 million and EPS of US$0.53 in Q3 2024 to the current Q4 2025 levels. Trailing twelve month EPS has stepped up from US$2.16 to US$2.52 over the same comparison points, setting up a results season where...
NasdaqGS:IPGP
NasdaqGS:IPGPElectronic

IPG Photonics Leans On Defense And Medical To Redefine Growth Mix

IPG Photonics (NasdaqGS:IPGP) has introduced the CROSSBOW MINI High-Energy Laser system, a new scalable defense product aimed at countering drone threats. The company reports strong momentum in its medical business, supported by new product launches and a major customer win. Management has indicated that medical-related revenues are expected to double or triple in the next year. IPG Photonics, trading at about $153.91, has seen very strong recent share price performance, with the stock up...
NYSE:TFC
NYSE:TFCBanks

Assessing Truist Financial (TFC) Valuation After Recent Share Price Momentum And Earnings Expectations

Why Truist Financial is on investors’ radar Truist Financial (TFC) is back in focus after recent trading left the shares with a mixed return profile, including a small 1 day pullback but gains over the month and past 3 months. See our latest analysis for Truist Financial. While the 1 day share price return of a 0.33% decline to US$51.90 and the 7 day share price return of a 7.01% decline hint at some cooling after recent strength, the 30 day and 90 day share price returns of 3.82% and 18.17%...
NYSE:PSX
NYSE:PSXOil and Gas

How Investors Are Reacting To Phillips 66 (PSX) Dividend Hike After Strong Q4 Earnings

Phillips 66 recently reported fourth-quarter 2025 revenue of US$36,333 million and net income of US$2,906 million, and the board has approved a quarterly dividend of US$1.27 per share, payable on March 4, 2026, to shareholders of record on February 23, 2026. The combination of markedly higher quarterly earnings and a 5.8% dividend increase underscores how the company is using improved performance and portfolio changes to support shareholder payouts. We'll now examine how Phillips 66's...
NYSE:RPC
NYSE:RPCCapital Markets

Ridgepost Capital (RPC) Valuation Check After Rebrand And High P/E Versus Peers

Why Ridgepost Capital Is On Investors’ Radar Ridgepost Capital (RPC) recently rebranded from P10, Inc. This shift is putting fresh attention on how this multi asset class private market solutions provider is positioned across private equity, venture capital, impact investing, and private credit. See our latest analysis for Ridgepost Capital. At a latest share price of $8.70, Ridgepost Capital has seen a 2.35% 1 day share price return. Its 30 day share price return of 18.77% and 1 year total...
NasdaqGS:NVCR
NasdaqGS:NVCRMedical Equipment

NovoCure (NVCR) Is Up 8.4% After First-in-Decades Pancreatic Cancer Approval - Has The Bull Case Changed?

In February 2026, NovoCure announced that the U.S. FDA approved Optune Pax for adult patients with locally advanced pancreatic cancer, to be used alongside gemcitabine and nab-paclitaxel after the Phase 3 PANOVA-3 trial showed a statistically significant overall survival benefit without adding meaningful systemic side effects. This approval marks the first new treatment option for locally advanced pancreatic cancer in decades and further validates NovoCure’s Tumor Treating Fields technology...
NasdaqGS:DAWN
NasdaqGS:DAWNBiotechs

Does FMR’s Sharp Stake Cut in Day One Biopharmaceuticals (DAWN) Change the Bull Case?

On December 31, 2025, FMR LLC reduced its stake in Day One Biopharmaceuticals by 4,380,660 shares, cutting its position by 43.38% but still holding 5,717,008 shares, or 5.60% of the company. This large shift by a major institutional holder may prompt investors to reassess how Day One Biopharmaceuticals fits within broader biotechnology portfolios. Next, we’ll examine how FMR LLC’s sizeable reduction in ownership could influence Day One Biopharmaceuticals’ investment narrative and risk...